SS

Swati Sinha

Active Director Director DIN 08984560
DIN 08984560 First appointment Dec 2020 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2020
Shareholding value •••• Premium profile

About Swati Sinha

Data last updated:

Swati Sinha is a Director at Zencorp Pharmaceutical Private Limited (since 2020). The company operates in Pharma. Zencorp Pharmaceutical Private Limited reported revenue of ₹23.8 Lakh (FY 2023).

DIN 08984560
Primary Designation Director
Industry Pharma
First Appointment 07 Dec 2020
Oldest Company Age 5 yrs
Largest company Zencorp Pharmaceutical Private Limited · ₹23.8 Lakh (FY 2023)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director07 Dec 20202020₹23.8 Lakh (FY 2023)Active

Board colleagues of Swati Sinha

NameDINCompanyDesignation
Neeraj Kumar08984547Zencorp Pharmaceutical Private LimitedDirector

Directorship timeline

Open interactive timeline →
Zencorp Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Swati Sinha

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Swati Sinha

Swati Sinha currently holds 1 directorship: Zencorp Pharmaceutical Private Limited (Director, since 07 Dec 2020, revenue ₹23.8 Lakh (FY 2023)).

Swati Sinha was first appointed on 07 Dec 2020 as Director at Zencorp Pharmaceutical Private Limited.

The current boards of Swati Sinha's companies include Neeraj Kumar (Zencorp Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available